An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen

Abstract excerpt

The threat to global health caused by three highly pathogenic human coronaviruses (HCoV), SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV therapeutics and vaccines. This study reports the design and engineering of a recombinant protein designated HR1LS. It contains three linked molecules, each consisting of three structural domains, including a heptad repeat 1 (HR1), a central helix (CH),...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Animal Virus Infections Studies
• Share to SARS-CoV-2 and COVID-19 Research
• Share to Viral gastroenteritis research and epidemiology